Shield Therapeutics is a patient-focused, commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product ACCRUFeR®/FERACCRU® (ferric maltol), a novel, stable, non-salt-based oral therapy for adults with iron deficiency, with or without anemia.
